Novo Nordisk A/S confirms Wegovy pill recommended by CHMP for approval in the EU as the first oral GLP-1 representing the most efficacious oral obesity treatment in its class
[출처/시간] Briefing.com - 9:25 AM ET, 05/22/2026 With a mean weight loss of 16.6%1, Wegovy pill demonstrates best-in-class weight-loss efficacy and is the first oral GLP-1 treatment recommended by CHMP for weight management in the EU.CHMP recommends Wegovy pill for approval to reduce excess body weight and maintain long-term weight reduction. The recommendation also includes data from SELECT which demonstrates that Weg
[출처/시간] Briefing.com - 9:25 AM ET, 05/22/2026
With
a mean weight loss of 16.6%1, Wegovy pill
demonstrates best-in-class weight-loss efficacy and is the first oral
GLP-1 treatment recommended by CHMP for weight management in the EU.CHMP
recommends Wegovy pill for approval to reduce excess body
weight and maintain long-term weight reduction. The recommendation also
includes data from SELECT which demonstrates that Wegovy reduces the risk of major adverse cardiovascular events (MACE)*, in the
label.Wegovy pill is the only oral GLP-1 treatment with no drug-drug restrictions in
the label.Novo
Nordisk plans to launch Wegovy pill in select markets outside
the US in the second half of 2026.
당신의 반응은 무엇인가요?
좋아요
0
싫어요
0
사랑
0
재미있는
0
화난
0
슬프다
0
와우
0
